Reference: 1. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2018.
References: 1. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board–blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. 2. Landmark study shows once-monthly long-acting therapy INVEGA SUSTENNA® (paliperidone palmitate) significantly delayed time to relapse in patients with schizophrenia compared to daily oral antipsychotic [press release]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; May 5, 2014. 3. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. IMS Real-World Data. May 2010-December 2013. 4. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2018.